

RX.PA.046.MPC Vyepti® (eptinezumab-jjmr)

The purpose of this policy is to define the prior authorization process for Vyepti® (eptinezumab-jjmr).

Vyepti® (eptinezumab-jjmr) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventative treatment of migraine in adults.

PROCEDURE

A. Initial Authorization Criteria:

1. All requests must meet the following criteria:

- Member must be 18 years of age or older
- Member must have a diagnosis of chronic migraine defined as:
 - ≥ 15 headache days per month for at least 3 months
 - ≥ 8 migraine days per month for at least 3 months
- Must be prescribed by a neurologist or in consultation with a neurologist
- Member has documented trial and failure (at least 3 months) or intolerance to at least 2 prophylactic medications from the following medication classes:
 - Antidepressants
 - Anticonvulsants
 - Calcium Channel Blockers
 - Beta-blockers
- Member has documented trial and failure (at least 3 months) or intolerance to **ALL** of the following:
 - Aimovig (erenumab)
 - Emgality (galcanezumab)
- Member has documented trial and failure (at least 3 months) or intolerance to Botox (onabotulinumtoxinA)
- Must not be used in combination with any other CGRP antagonist medications

B. Must be prescribed at a dose within the manufacturer's dosing guidelines (based on diagnosis, weight, etc) listed in the FDA approved labeling.

C. Vyepti will be considered investigational or experimental for any other use and will not be covered.

D. Reauthorization Criteria:

- Member continues to be in compliance with initial criteria
- Documentation from the prescriber showing that the member has improved/stabilized based on the prescriber's assessment
 - Improvement in migraine frequency and severity
 - Reduction in migraine days
 - Reduced use of medications to manage acute migraine attacks

Quantity Limitations:

Length of Authorization (if above criteria met)	
Initial Authorization	6 months
Reauthorization	12 months

Codes:

Code	Description
J3032	Injection, eptinezumab-jjmr, 1mg

REFERENCES

1. Vypeti [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; September 2021.

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
<i>Annual Review</i>	<i>02/2022</i>
<i>Addition of dosing requirements</i>	<i>12/2021</i>
<i>New Policy</i>	<i>10/2021</i>